Market Overview

Akorn Shares Down 5+% Midday; Hearing RBC Analyst Out Cautious On The Name Citing Competition From Novartis' FDA Approved Atropine Sulfate

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: Movers

 

Related Articles (AKRX)

Partner Center